<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897802</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-OXI-2020-102</org_study_id>
    <nct_id>NCT04897802</nct_id>
  </id_info>
  <brief_title>Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)</brief_title>
  <official_title>Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the&#xD;
      posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology,&#xD;
      prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity,&#xD;
      increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone&#xD;
      replacement. A few studies suggest the existence of a possible OT deficient state in&#xD;
      hypopituitarism. In animal models, glucagon-like peptide 1 (GLP1) has shown to increase OT&#xD;
      release.&#xD;
&#xD;
      This study is designed to evaluate OT values after administration of GLP1 in adults (healthy&#xD;
      volunteers and patients with hypopituitarism).&#xD;
&#xD;
      The investigators hypothesize that OT response will be blunted following GLP1 receptor&#xD;
      agonist (GLP1-RA) in patients with hypopituitarism compared to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is focused on two groups of participants: healthy controls (HC) and&#xD;
      hypopituitary patients (HYPO) with at least one symptom of hypothalamic damage, presumably at&#xD;
      highest risk for OT deficiency.&#xD;
&#xD;
      The aim is to improve knowledge on the physiology and patho-physiology of endogenous OT&#xD;
      secretion in hypopituitary patients compared to healthy controls using a randomized,&#xD;
      single-blind, crossover assignment (GLP1-RA vs placebo), placebo-control design.&#xD;
&#xD;
      Clinical implications of secretory OT dynamics and release under different stimuli using&#xD;
      validated questionnaires to evaluate psychopathology, socio-emotional functioning, disordered&#xD;
      eating behavior, impaired quality of life and sexual dysfunction, will be also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in oxytocin concentration (pg/mL)</measure>
    <time_frame>Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>Change in oxytocin concentration (pg/mL) after administration of 10 µg of GLP1-RA (exenatide) or 0.9% sodium chloride (NaCl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal change in oxytocin concentration (pg/mL)</measure>
    <time_frame>Within the two hours after the injection</time_frame>
    <description>Change in oxytocin concentration (pg/mL) after administration of 10 µg of GLP1-RA (exenatide) or 0.9% NaCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall oxytocin secretion (pg/mL)</measure>
    <time_frame>Within the two hours after the injection</time_frame>
    <description>Oxytocin area under the curve after administration of 10 µg of GLP1-RA (exenatide) or 0.9% NaCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose concentration (mg/dL)</measure>
    <time_frame>Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>Change in glucose concentration (mg/dL) after administration of 10 µg of GLP1-RA (exenatide) or 0.9% NaCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin concentration (pmol/L)</measure>
    <time_frame>Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection</time_frame>
    <description>Change in insulin concentration (pmol/L) after administration of 10 µg of GLP1-RA (exenatide) or 0.9% NaCl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Association between Beck Depression Inventory-2 score (range from 0 to 63, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Association between 36-item Short Form Health Survey score (range from 0 to 100, the higher scores indicate better health status) and baseline oxytocin concentration (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulsivity assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Association between Barratt Impulsiveness Scale (range from 30 to 120, higher scores indicate greater impulsivity) and baseline oxytocin concentration (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexithymia assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Association between Toronto Alexithymia scales-20 score (range from 20 to 100, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hypopituitarism</condition>
  <condition>Central Diabetes Insipidus</condition>
  <condition>Panhypopituitarism</condition>
  <condition>Psychological Disorder</condition>
  <condition>Social Isolation</condition>
  <condition>Hypothalamic Diseases</condition>
  <condition>Pituitary Diseases</condition>
  <condition>Oxytocin Deficiency</condition>
  <arm_group>
    <arm_group_label>Experimental: GLP1-RA administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 10 mcg of GLP1-RA (exenatide) will be injected subcutaneously and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after GLP1-RA:placebo administration to assess OT secretory patterns</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than GLP1-RA (exenatide) administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: GLP1-RA (exenatide) administration</intervention_name>
    <description>a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours</description>
    <arm_group_label>Experimental: GLP1-RA administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control: Placebo administration</intervention_name>
    <description>Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide</description>
    <arm_group_label>Control: Placebo administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hypopituitarism (HYPO) (&gt;1 pituitary hormone deficiency) and stable&#xD;
             hormone replacement for the prior three months&#xD;
&#xD;
          -  At least one clinical sign of hypothalamic damage&#xD;
&#xD;
          -  Female participants will be done in the early to midfollicular phase&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncorrected hormone deficiency&#xD;
&#xD;
          -  creatinine &gt;1.5mg/dL&#xD;
&#xD;
          -  alanine aminotransferase (ALT) or aspartate amino transferase (AST) &gt;2.5x upper limit&#xD;
             of normal&#xD;
&#xD;
          -  hematocrit less than 30%&#xD;
&#xD;
          -  suicidality or active psychosis&#xD;
&#xD;
          -  participation in a trial with investigational drugs within 30 days&#xD;
&#xD;
          -  using a high glucocorticoid dose&#xD;
&#xD;
          -  Any type of diabetes mellitus&#xD;
&#xD;
          -  Obese patients on GLP1-RA therapies&#xD;
&#xD;
          -  vigorous physical exercise&#xD;
&#xD;
          -  alcohol intake within 24 hours before the study participation&#xD;
&#xD;
          -  evidence of any acute illness or any illness that the Investigator determines could&#xD;
             interfere with study participation or safety&#xD;
&#xD;
          -  pregnancy or breastfeeding for last 8 weeks&#xD;
&#xD;
          -  known allergies towards GLP1-RA&#xD;
&#xD;
          -  patients refusing or unable to give written informed consent&#xD;
&#xD;
          -  Additionally for healthy controls: the presence of brain or pituitary tumor, radiation&#xD;
             involving the hypothalamus or pituitary, history of hypopituitarism or receiving&#xD;
             testosterone or glucocorticoids esters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Aulinas, MD PhD</last_name>
    <phone>+34 932919000</phone>
    <phone_ext>7917</phone_ext>
    <email>aaulinas@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>hypopituitarism</keyword>
  <keyword>diabetes insipidus</keyword>
  <keyword>hypothalamic-pituitary diseases</keyword>
  <keyword>psychopathology</keyword>
  <keyword>exenatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Hypopituitarism</mesh_term>
    <mesh_term>Hypothalamic Diseases</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Insipidus, Neurogenic</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

